Bicycle Therapeutics plc APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Bicycle Therapeutics plc (BCYC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.40M, a 32.13% decline year-over-year.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.93M, a 27.85% decline year-over-year.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.77M, a 4.68% decline year-over-year.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $9.44M, a 1.85% increase year-over-year.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $39.46M, a 3.63% increase from fiscal 2024.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $38.08M, a 17.26% increase from fiscal 2023.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $32.48M, a 21.28% increase from fiscal 2022.
- Bicycle Therapeutics plc apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $26.78M, a 121.63% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.40M 10-Q · filed 2026-07-30 | $13.33M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $6.93M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $39.46M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $8.77M 10-Q · filed 2025-10-30 | $18.21M derived: sum of 2 quarters · filed 2026-07-30 | $27.81M derived: sum of 3 quarters · filed 2026-07-30 | |
| 2025-06-30 | $9.44M 10-Q · filed 2026-07-30 | $19.04M derived: sum of 2 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $9.61M 10-Q · filed 2026-07-30 | |||
| 2024-12-31 | $38.08M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $9.20M 10-Q · filed 2025-10-30 | $18.47M derived: sum of 2 quarters · filed 2025-10-30 | $27.75M derived: sum of 3 quarters · filed 2025-10-30 | |
| 2024-06-30 | $9.26M 10-Q · filed 2025-10-30 | $18.55M derived: sum of 2 quarters · filed 2025-10-30 | ||
| 2024-03-31 | $9.28M 10-Q · filed 2025-10-30 | |||
| 2023-12-31 | $32.48M 10-K · filed 2026-03-17 | |||
| 2023-09-30 | $7.43M 10-Q · filed 2024-10-31 | $15.62M derived: sum of 2 quarters · filed 2024-10-31 | $24.66M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $8.19M 10-Q · filed 2024-10-31 | $17.23M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $9.04M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $26.78M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $5.37M 10-Q · filed 2023-11-02 | $11.04M derived: sum of 2 quarters · filed 2023-11-02 | $21.24M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $5.67M 10-Q · filed 2023-11-02 | $15.87M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $10.20M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $12.08M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | $2.69M 10-Q · filed 2022-11-03 | $5.26M derived: sum of 2 quarters · filed 2022-11-03 | $9.08M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $2.58M 10-Q · filed 2022-11-03 | $6.40M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $3.82M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $6.51M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $1.51M 10-Q · filed 2021-11-04 | $2.83M derived: sum of 2 quarters · filed 2021-11-04 | $4.95M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $1.32M 10-Q · filed 2021-11-04 | $3.44M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $2.12M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $2.69M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $819.00K 10-Q · filed 2020-11-05 | $1.43M derived: sum of 2 quarters · filed 2020-11-05 | $1.60M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $612.00K 10-Q · filed 2020-11-05 | $784.00K derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $172.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $800.00K 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $203.00K 10-Q · filed 2019-11-07 | $512.00K derived: sum of 2 quarters · filed 2019-11-07 | $710.00K derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-06-30 | $309.00K 10-Q · filed 2019-11-07 | $507.00K derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2018-03-31 | $198.00K 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $401.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |